Abstract
No public abstract is available from the verified source records.
Jiwen Fan, Wenjuan Lai, Boran Cheng, Meijing Chen, Shubin Wang, Gangling Tong
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Colorectal cancer statistics, 2026
2026
Research trends on chemotherapy induced nausea and vomiting: A bibliometric analysis
10.3389/fphar.2024.1369442 · 2024
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk
10.1186/s12885-021-08860-y · 2021
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial
10.1016/s1470-2045(19)30862-9 · 2020
2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients
2024
Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO)
10.1016/j.ejca.2022.01.028 · 2022
Netupitant-palonosetron (NEPA) for preventing Chemotherapy-induced nausea and Vomiting: From clinical trials to daily practice
10.2174/1568009622666220513094352 · 2022
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/j.esmoop.2023.102195 · 2024
NEPA (Netupitant/Palonosetron) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately emetogenic chemotherapy who experienced breakthrough CINV in cycle 1 of chemotherapy: A phase II clinical trial
10.1002/cam4.70549 · 2025
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: A real-life study
2021
Effect of adding electroacupuncture to standard triple antiemetic therapy on Chemotherapy-Induced nausea and vomiting: A randomized controlled clinical trial
10.1200/jco.24.00099 · 2024
Risk prediction model for chemotherapy-induced nausea and vomiting in cancer patients: A systematic review
10.1016/j.ijnurstu.2025.105094 · 2025
A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy
2026
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: Results from the randomised, multinational MyRisk trial
10.1016/j.annonc.2025.10.017 · 2026
Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
10.1016/j.eclinm.2022.101480 · 2022
Efficacy of Olanzapine-Triple antiemetic regimen in patients with gastrointestinal tumor and high risk of Chemotherapy-Induced nausea and vomiting receiving moderately emetogenic chemotherapy: A retrospective study
10.2147/cmar.s254398 · 2020
Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: A meta-analysis of randomized controlled trials
10.1093/oncolo/oyae233 · 2025
An Open-Label, Single-Arm, multicenter, observational study evaluating the safety and effectiveness of Akynzeo® in the management of Chemotherapy-induced nausea and vomiting in india
2024
A pragmatic study evaluating NEPA versus aprepitant for prevention of Chemotherapy-Induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
10.1002/onco.13888 · 2021
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies
10.1002/cam4.2091 · 2019
Prevalence and predictors of long-delayed (>120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis
2023
A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers
10.1007/s00280-020-04200-2 · 2021
Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice
10.1111/bph.13646 · 2016
Efficacy of single low-dose dexamethasone with NEPA for the 168 h prevention of highly or moderately emetogenic chemotherapy
10.3389/fphar.2025.1622789 · 2025
Efficacy and safety of cinobufacini capsules combined with oxaliplatin-based chemotherapy for advanced colorectal cancer: A human systematic review and meta-analysis
10.3389/fphar.2026.1709044 · 2026
No additional external references are available.